LXRX News - Candlesense

Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025

(NASDAQ:LXRX) THE WOODLANDS, Texas, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the Company will present new data demonstrating the reduct...

Clinical trials

7 days ago

Read more globenewswire

Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025

(NASDAQ:LXRX) THE WOODLANDS, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced data from a study of patients describing the physical and psych...

Clinical trials

8 days ago

Read more globenewswire

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences

THE WOODLANDS, Texas, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at Citi's Biopharm...

Investor events

15 days ago

Read more globenewswire

Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights

What potential risks or uncertainties were highlighted in the MD&A that traders should monitor moving forward? Did the company provide any updates on its product pipeline that could affect long‑term valuation? What is the market's reaction to the earnings release, and are there any notable changes in trading volume or short interest?

Earnings

28 days ago

Read more globenewswire